LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates
Expanded agreement grants Iksuda access to Legochem Biosciences’ next generation ADC platform for up
Expanded agreement grants Iksuda access to Legochem Biosciences’ next generation ADC platform for up
Funding to accelerate clinical progression of Iksuda’s pipeline of new generation of antibody drug